v3.26.1
LICENSING AGREEMENTS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Feb. 28, 2022
Dec. 28, 2020
May 17, 2017
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Aug. 31, 2023
Sep. 30, 2021
Jan. 31, 2021
Dec. 31, 2020
Dec. 12, 2020
Feb. 02, 2016
Number of shares                       43,112
Additional CMH payment       $ 50,000                
Obligation due under agreement through the issuance of common stocks       300,000                
Payment for clinical trial       200,000                
Common stock value       3,144   $ 3,144           $ 100,000
Patents gross       $ 300,000                
Total obligation under the agreement               $ 300,000   $ 100,000 $ 300,000  
Initial payment of obligation               $ 40,000   $ 50,000 $ 50,000  
Balance of obligation, description       The remaining portion of the $300,000 obligation was paid in cash in 2020                
Remaining portion of obligation             $ 100,000          
Amortization       $ 28,855 $ 30,577              
Amortization expenses       $ 11,524 11,485              
Common stock shares       3,701,668   3,701,668            
Description of payment on conversion basis     Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date                  
Description for the consecutive trading days     In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles                  
Payments upon completion of the IRB clinical trial     $ 200,000                  
Payments in the event of commercialization of technology       $ 300,000                
Licensing Agreements [Member]                        
Amortization       0                
Payments upon dosing of the first patient in Phase 3 clinical trial       100,000                
License Agreement [Member]                        
Amortization expenses       0 293              
Carrying value of patent       0                
Jadi Cell [Member]                        
Pyment for license fees $ 250,000 $ 250,000                    
Common stock shares 18,018                      
StemSpine LLC [Member]                        
Amortization       2,736 2,500              
Carrying value of patent       $ 11,402                
Expiration period of finite-lived intangible assets       May 19, 2027                
Amortization       $ 11,402                
Option Warrant [Member]                        
Amortization       6,161 6,250              
Carrying value of patent       118,764                
Amortization       25,000                
Initial payment     100,000                  
Payments upon dosing of the first patient in Phase 3 clinical trial     400,000 100,000                
Payments upon dosing of the first patient first patient in a Phase 1-2 clinical trial     $ 200,000                  
ImmCelz Patent [Member]                        
Common stock, shares               8,466 8,929   667  
Patents gross       $ 200,000                
Discount rate       25.00%                
Amortization expenses       $ 4,929 4,929              
Interest rate       5.00%                
Carrying value of patent       $ 166,730                
Exercise price       $ 0.0037                
Amortization       $ 20,000                
EDI Patent [Member]                        
Amortization       1,042 2,493              
Carrying value of patent       0                
IND [Member]                        
Patents gross       100,000                
Amortization       2,463 $ 2,463              
Carrying value of patent       75,031                
Amortization       10,000                
Patents [Member]                        
Carrying value of patent       6,447                
Amortization       $ 6,447